在这一年的交易热潮中，跨国巨头们的采购风格各有不同。谁出手频次最高？谁手笔最大？经济观 察报分析了全年150多笔交易，复盘跨国药企的投资画像与交易特色。 多位受访者对经济观察报表示，其所在药企与潜在合作方达成了进一步沟通意向，他们判断2026 年中国创新药对外授权交易热仍会持续。 2025年爆发式增长的对外授权交易验证了中国创新药资产的价值，该年对外授权总交易额超1300 亿美元，交易数超150笔（约占全球40%），创下历史新高。 阿斯利康最活跃 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共出手了5次。 合作方包括石药集团（01093.HK）、和铂医药（02142.HK）、加科思药业（01167.HK）、元 思生肽等。其中，在2025年6月与石药集团达成的潜在总交易额超53亿美元的合作，可排进年度 交易额前四。在资产选择上，阿斯利康主要集中在临床早期管线，以及技术平台合作。 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共 出手了5次。从立即兑现的首付款看，辉瑞与武田制药出手最 阔绰。 作者：张英 封图：图虫创意 作为中国市场销售额最高的外资药企，在经历2024年的公司治理风暴后，阿斯利康 ...

Group 1: Overview of Guangdong Products - The "Guangdong Products Going Global" initiative is gaining momentum as the Spring Festival approaches, with a focus on promoting local goods both online and offline [3] - Guangdong products, ranging from traditional items like Guangzhou flower arrangements to innovative industrial and biopharmaceutical products, are becoming a significant part of the consumer market [3] - The success of Guangdong products is attributed to rich innovation stories and significant industry transformations [3] Group 2: Drone Industry - Guangdong's drone industry, exemplified by Chengzhi Intelligent, has seen significant growth, with products sold in over 50 countries [6] - Chengzhi Intelligent focuses on developing various drone payloads for emergency rescue and public safety applications, showcasing strong innovation and quality [7] - The company's products gained popularity through word-of-mouth and social media, highlighting the importance of innovation in global marketing [7] Group 3: Lighting and Home Appliances - The lighting industry in Zhongshan is evolving with a focus on customization and technology, moving from standardized to tailored products [10] - Companies are addressing market challenges by innovating and finding user pain points, demonstrating a commitment to quality and technological advancement [11] - The success of these companies is attributed to their ability to adapt and innovate within traditional sectors [11] Group 4: Biopharmaceutical Industry - The Guangdong biopharmaceutical sector is undergoing a transformation, moving from traditional herbal medicine to cutting-edge technologies that influence global health guidelines [13][15] - Companies like Dabo Biotech and Shiyao Mingfu are facing challenges in funding and regulatory processes, emphasizing the resilience required in the industry [14] - The government is responding to industry needs with new policies aimed at facilitating the development of innovative drugs [14] Group 5: Floral Industry - Guangzhou's floral industry is a significant economic contributor, with a market size exceeding 30 billion yuan and annual exports over 1.2 billion yuan [18][19] - Local representatives and businesses are actively promoting the floral industry, showcasing its potential for growth and innovation [20] - The collaboration among various stakeholders, including farmers and tech developers, is vital for sustaining the industry's vitality [20] Group 6: Film and Entertainment Industry - Guangdong's film industry is recognized as a leading market in China, supported by innovative practices in cinema operations and audience engagement [23] - The province's policy support for cultural industries has fostered a thriving environment for film production and creativity [24] - Recent successes in animation and film highlight the advancements in technology and storytelling within the Guangdong entertainment sector [24]

Core Insights - The 2026 JPMorgan Healthcare Conference highlighted significant interest from multinational companies in Chinese assets, particularly in the innovative drug sector [1][2] Group 1: Market Trends - The trend of foreign licensing deals for Chinese innovative drugs is expected to continue in 2026, following a record-breaking year in 2025 where the total licensing deal value exceeded $130 billion, accounting for approximately 40% of global transactions [3] - The surge in licensing deals in 2025 validated the value of Chinese innovative drug assets, with over 150 transactions recorded [3] Group 2: Key Players - AstraZeneca emerged as the most active multinational company in 2025, engaging in five transactions, including a notable deal with CSPC Pharmaceutical Group valued at over $5.3 billion [4] - Pfizer and Eli Lilly each conducted four transactions, with Pfizer's deal with 3SBio setting a record for upfront payments in Chinese innovative drugs at $1.25 billion [5] - GSK's collaboration with Heng Rui Medicine reached a potential total of $12.5 billion, marking the highest deal value for Chinese innovative drugs [13] Group 3: Emerging Markets - Interest in Chinese innovative drugs is not limited to Western companies; firms from India, Latin America, and the Middle East are also engaging in licensing deals [7] - Indian companies Glenmark and Dr. Reddy's each completed two business development transactions in 2025, with Glenmark's deals totaling over $2 billion [8][9] Group 4: Financial Highlights - Three companies, AstraZeneca, GSK, and Takeda, signed contracts exceeding $10 billion, while Pfizer and Novartis secured contracts over $5 billion [10] - The largest single transaction was GSK's deal with Heng Rui Medicine, which included rights to one core drug and options for 11 additional projects [13] Group 5: Future Outlook - Executives at the 2026 JPM conference expressed that Chinese assets are an effective way to supplement pipelines, indicating a shift towards acquiring entire biotechnology platforms rather than just single products [14]

Group 1: Guangdong Products and Market Trends - The "Guangdong Products Going Global" spring campaign is gaining traction, showcasing a variety of Guangdong goods that blend traditional craftsmanship with modern technology [2][4] - Guangdong's flower industry is a significant sector, with a market scale exceeding 30 billion yuan and an annual import-export value of over 1.2 billion yuan, making it the largest small potted plant production base in China [14][16] - The Guangdong film industry is experiencing growth, supported by government policies aimed at high-quality cultural development, which includes various sectors such as film and animation [44][45] Group 2: Innovation in Traditional Industries - The lighting industry in Zhongshan is shifting from standardization to customization, with companies focusing on technology-intensive solutions to meet diverse consumer needs [6][8] - Guangdong's biopharmaceutical sector is evolving from traditional herbal medicine to cutting-edge technologies, with companies like Kangfang Biotech achieving significant international milestones [28][30] - The drone industry in Guangdong is represented by companies like Chengzhi Intelligent, which has developed innovative products for emergency rescue operations, gaining popularity in over 50 countries [22][26] Group 3: Community and Collaborative Efforts - Local representatives and community members are actively promoting the flower industry, emphasizing the importance of collective efforts in sustaining the sector's vitality [16][19] - The Guangdong film industry benefits from collaboration among various stakeholders, including cinema operators and technology providers, enhancing the overall viewing experience [40][42] - The biopharmaceutical industry is seeing increased support from local governments, responding to the challenges faced by small and medium-sized biotech firms [32][34]

证券代码：688177 证券简称：百奥泰 公告编号：2026-005 百奥泰生物制药股份有限公司 关于归还临时补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2026 年 1 月 22 日，公司已累计归还临时补充流动资金的闲置募 集资金人民币 10,000 万元。 百奥泰生物制药股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开 第三届董事会第二次会议和第三届董事会审计委员会第二次会议，审议通过了 《关于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司在确保不影 响募集资金投资项目实施及募集资金使用的情况下，使用不超过人民币 1 亿元闲 置募集资金暂时补充流动资金，使用期限自董事会审议通过之日起不超过 12 个 月，并且公司将随时根据募投项目的进展及需求情况及时归还至募集资金专用账 户 。 具 体 内 容 详 见 公 司 于 2025 年 8 月 21 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）和指定媒体刊登的《百奥 ...

Key Points - Hunan Silver's future market price for silver products has uncertainty regarding its ability to continue rising or maintain high levels [1] - Zhite New Materials may apply for a trading suspension again if its stock price experiences further abnormal increases [1] - Binhai Energy plans to invest in the construction of porous carbon and silicon-carbon anode material projects [1] - Baotai's subsidiary signed a construction contract worth 85.5626 million yuan with an affiliated party [1] - Limin Co. expects a net profit growth of 471.55%-514.57% year-on-year for 2025 [1] - Han Jian Heshan intends to acquire 52.51% equity in Xingfu New Materials, with trading suspension starting January 22 [2] - Xingfa Group plans to repurchase company shares with an investment of 200 million to 400 million yuan [1] - Actual controller of Hengshuai Co. plans to reduce holdings by no more than 2.16% [1] - Lu Wei Optoelectronics intends to raise no more than 1.38 billion yuan through a private placement [1]

证券代码：688177 证券简称：百奥泰 公告编号：2026-003 百奥泰生物制药股份有限公司 关于全资子公司与关联方签订建设工程施工合同 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 交易内容：百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"） 全资子公司百奥泰生物药业（广州）有限公司（以下简称"百奥泰药业"）拟与 公司关联方潜江市水牛建筑工程有限公司（以下简称"水牛建筑"）就百奥泰永 和创新产业基地签订《建设工程施工合同》，合同价格为人民币 85,562,617.34 元（以下简称"本次关联交易"），本次关联交易属于公司正常生产经营活动。 水牛建筑为百奥泰实际控制人控制的企业，本次交易构成关联交易，但 不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 本次交易实施不存在重大法律障碍。 本次关联交易已经公司第三届董事会第六次会议、第三届董事会审计委 员会及第三届董事会独立董事第二次专门会议审议通过，尚需提交公司股东会 审议。 一、关联交易概述 公司全资子公司百奥泰药 ...

百奥泰生物制药股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 证券代码：688177 证券简称：百奥泰 公告编号：2026-004 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 召开日期时间：2026 年 2 月 6 日 14 点 00 分 召开地点：广州市国际生物岛螺旋二路 18 号百奥泰创新中心一楼展厅 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 6 日 至2026 年 2 月 6 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 股东会召开日期：2026年2月6日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） ...

格隆汇1月21日丨百奥泰(688177.SH)公布，公司全资子公司百奥泰药业拟与水牛建筑就百奥泰永和创新 产业基地的建设施工服务及有关事项签署《建设工程施工合同》，本次定价根据第三方工程造价预算为 基础，合同价格为人民币8556.26万元。 ...

格隆汇1月21日丨百奥泰(688177.SH)公布，公司全资子公司百奥泰药业拟与水牛建筑就百奥泰永和创新 产业基地的建设施工服务及有关事项签署《建设工程施工合同》，本次定价根据第三方工程造价预算为 基础，合同价格为人民币8556.26万元。 ...